B-intervention	0	8	Sentinel
I-intervention	9	13	node
I-intervention	14	20	biopsy
O	21	29	compared
O	30	34	with
B-control	35	43	complete
I-control	44	52	axillary
I-control	53	63	dissection
O	64	67	for
O	68	75	staging
B-eligibility	76	81	early
I-eligibility	82	88	breast
I-eligibility	89	95	cancer
I-eligibility	96	100	with
I-eligibility	101	111	clinically
I-eligibility	112	120	negative
I-eligibility	121	126	lymph
I-eligibility	127	132	nodes
O	132	133	:
O	134	141	results
O	142	144	of
O	145	155	randomized
O	156	161	trial
O	161	162	.

O	163	171	Sentinel
O	172	177	lymph
O	178	182	node
O	183	184	(
O	184	187	SLN
O	187	188	)
O	189	196	staging
O	197	199	is
O	200	209	currently
O	210	214	used
O	215	217	to
O	218	223	avoid
O	224	232	complete
O	233	241	axillary
O	242	252	dissection
O	253	255	in
O	256	262	breast
O	263	269	cancer
O	270	278	patients
O	279	283	with
O	284	292	negative
O	293	297	SLNs
O	297	298	.

O	299	307	Evidence
O	308	310	of
O	311	312	a
O	313	320	similar
O	321	329	efficacy
O	329	330	,
O	331	333	in
O	334	339	terms
O	340	342	of
O	343	351	survival
O	352	355	and
O	356	364	regional
O	365	372	control
O	372	373	,
O	374	376	of
O	377	381	this
O	382	390	strategy
O	391	393	as
O	394	402	compared
O	403	407	with
O	408	416	axillary
O	417	426	resection
O	427	429	is
O	430	435	based
O	436	438	on
O	439	442	few
O	443	451	clinical
O	452	458	trials
O	458	459	.

O	460	462	In
O	463	467	1998
O	467	468	,
O	469	471	we
O	472	479	started
O	480	481	a
O	482	492	randomized
O	493	498	study
O	499	508	comparing
O	509	512	the
O	513	516	two
O	517	527	strategies
O	527	528	,
O	529	532	and
O	533	535	we
O	536	543	present
O	544	548	here
O	549	552	its
O	553	560	results
O	560	561	.

O	562	570	Patients
O	571	575	were
O	576	584	randomly
O	585	593	assigned
O	594	596	to
O	597	605	sentinel
O	606	611	lymph
O	612	616	node
O	617	623	biopsy
O	624	625	(
O	625	629	SLNB
O	629	630	)
O	631	634	and
O	635	643	axillary
O	644	654	dissection
O	655	656	[
O	656	664	axillary
O	665	670	lymph
O	671	675	node
O	676	686	dissection
O	687	688	(
O	688	692	ALND
O	693	696	arm
O	696	697	)
O	697	698	]
O	699	701	or
O	702	704	to
O	705	709	SLNB
O	710	714	plus
O	715	723	axillary
O	724	733	resection
O	734	736	if
O	737	741	SLNs
O	742	751	contained
O	752	762	metastases
O	763	764	(
O	764	768	SLNB
O	769	772	arm
O	772	773	)
O	773	774	.

O	775	779	Main
O	780	783	end
O	784	790	points
O	791	795	were
B-outcome-Measure	796	803	overall
I-outcome-Measure	804	812	survival
I-outcome-Measure	813	814	(
I-outcome-Measure	814	816	OS
I-outcome-Measure	816	817	)
O	818	821	and
B-outcome-Measure	822	830	axillary
I-outcome-Measure	831	841	recurrence
O	841	842	.

B-control-participants	843	846	One
I-control-participants	847	854	hundred
I-control-participants	855	858	and
I-control-participants	859	866	fifteen
O	867	875	patients
O	876	880	were
O	881	889	assigned
O	890	892	to
O	893	896	the
O	897	901	ALND
O	902	905	arm
O	906	909	and
B-intervention-participants	910	913	110
O	914	916	to
O	917	920	the
O	921	925	SLNB
O	926	929	arm
O	929	930	.

O	931	932	A
B-outcome	933	941	positive
I-outcome	942	945	SLN
O	946	949	was
O	950	955	found
O	956	958	in
B-cv-bin-abs	959	961	27
O	962	970	patients
O	971	973	in
O	974	977	the
O	978	982	ALND
O	983	986	arm
O	987	990	and
O	991	993	in
B-iv-bin-abs	994	996	31
O	997	999	in
O	1000	1003	the
O	1004	1008	SLNB
O	1009	1012	arm
O	1012	1013	.

B-outcome	1014	1021	Overall
I-outcome	1022	1030	accuracy
O	1031	1033	of
O	1034	1038	SLNB
O	1039	1042	was
B-iv-bin-percent	1043	1045	93
I-iv-bin-percent	1045	1046	.
I-iv-bin-percent	1046	1047	0
I-iv-bin-percent	1047	1048	%
O	1048	1049	.

B-outcome	1050	1061	Sensitivity
O	1062	1065	and
B-outcome	1066	1074	negative
I-outcome	1075	1085	predictive
I-outcome	1086	1092	values
O	1093	1097	were
B-iv-bin-percent	1098	1100	77
I-iv-bin-percent	1100	1101	.
I-iv-bin-percent	1101	1102	1
I-iv-bin-percent	1102	1103	%
O	1104	1107	and
B-iv-bin-percent	1108	1110	91
I-iv-bin-percent	1110	1111	.
I-iv-bin-percent	1111	1112	1
I-iv-bin-percent	1112	1113	%
O	1113	1114	,
O	1115	1127	respectively
O	1127	1128	.

O	1129	1131	At
O	1132	1133	a
O	1134	1140	median
O	1141	1147	follow
O	1147	1148	-
O	1148	1150	up
O	1151	1153	of
O	1154	1155	5
O	1155	1156	.
O	1156	1157	5
O	1158	1163	years
O	1163	1164	,
B-iv-bin-abs	1165	1167	no
B-outcome	1168	1176	axillary
I-outcome	1177	1187	recurrence
O	1188	1191	was
O	1192	1200	observed
O	1201	1203	in
O	1204	1207	the
O	1208	1212	SLNB
O	1213	1216	arm
O	1216	1217	.

B-outcome	1218	1220	OS
O	1221	1224	and
B-outcome	1225	1230	event
I-outcome	1230	1231	-
I-outcome	1231	1235	free
I-outcome	1236	1244	survival
O	1245	1249	were
O	1250	1253	not
O	1254	1267	statistically
O	1268	1277	different
O	1278	1285	between
O	1286	1289	the
O	1290	1293	two
O	1294	1298	arms
O	1298	1299	.

O	1300	1303	The
O	1304	1308	SLNB
O	1309	1318	procedure
O	1319	1323	does
O	1324	1327	not
O	1328	1334	appear
O	1335	1343	inferior
O	1344	1346	to
O	1347	1359	conventional
O	1360	1364	ALND
O	1365	1368	for
O	1369	1372	the
O	1373	1379	subset
O	1380	1382	of
O	1383	1391	patients
O	1392	1396	here
O	1397	1407	considered
O	1407	1408	.
